Microtubules and resistance to tubulin-binding agents

Nature Reviews Cancer 10, 194–204 (2010) On page 202 of this article, extracellular matrix transforming growth factor-β1 (TGFβ1), should have read extracellular matrix transforming growth factor-β induced (TGFβI). This has been corrected online.

[1]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[2]  Benjamin J Vakoc,et al.  Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging , 2009, Nature Medicine.

[3]  J. Baselga,et al.  Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Toshikazu Nakamura,et al.  Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition. , 2006, Experimental cell research.

[5]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[6]  Maria Kavallaris,et al.  Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – An in vivo study , 2006, Proteomics.

[7]  A. Giordano,et al.  Differential expression and cellular distribution of γ‐tubulin and βIII‐tubulin in medulloblastomas and human medulloblastoma cell lines , 2010, Journal of cellular physiology.

[8]  F. Mollinedo,et al.  Microtubules, microtubule-interfering agents and apoptosis , 2003, Apoptosis.

[9]  Hanno Steen,et al.  Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: A quantitative proteomic analysis , 2008, Proceedings of the National Academy of Sciences.

[10]  M. Herman,et al.  Class III β-tubulin in human development and cancer† , 2003 .

[11]  W. M. Smit,et al.  Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  O. Bernard.  Lim kinases, regulators of actin dynamics. , 2007, The international journal of biochemistry & cell biology.

[13]  E. Pasquier,et al.  Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .

[14]  M. Kavallaris,et al.  Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. , 2005, Current pharmaceutical design.

[15]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[16]  Stefan Westermann,et al.  Post-translational modifications regulate microtubule function , 2003, Nature Reviews Molecular Cell Biology.

[17]  M. Kavallaris,et al.  Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. , 2004, Molecular cancer therapeutics.

[18]  W. Hait,et al.  Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells , 2007, Molecular Pharmacology.

[19]  C. Dumontet,et al.  Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy , 2005, Clinical Cancer Research.

[20]  Nizar M. Mhaidat,et al.  Melanoma cell sensitivity to Docetaxel‐induced apoptosis is determined by class III β‐tubulin levels , 2008, FEBS letters.

[21]  Leslie Wilson,et al.  βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability* , 2005, Journal of Biological Chemistry.

[22]  Nasser M. Rusan,et al.  Cell Cycle-Dependent Changes in Microtubule Dynamics in Living Cells Expressing Green Fluorescent Protein-α Tubulin , 2001 .

[23]  E. Thomas.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[25]  P. Hains,et al.  Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.

[26]  Helder Maiato,et al.  Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. , 2004, Developmental cell.

[27]  D. Katsaros,et al.  Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel , 2009, Cancer.

[28]  Hailing Yang,et al.  Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. , 2003, Cell motility and the cytoskeleton.

[29]  B. Teicher.  Acute and chronic in vivo therapeutic resistance. , 2009, Biochemical pharmacology.

[30]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[31]  S. Moody,et al.  Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene. , 2002, Gene.

[32]  A. Frankfurter,et al.  β class II tubulin predominates in normal and tumor breast tissues , 2003, Breast Cancer Research.

[33]  C. Waterman-Storer,et al.  Conserved microtubule–actin interactions in cell movement and morphogenesis , 2003, Nature Cell Biology.

[34]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[35]  E. Martinelli,et al.  Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. , 2007, Gynecologic oncology.

[36]  P. Gunning,et al.  Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia , 2006 .

[37]  Ben Cornett,et al.  The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography , 2004, Science.

[38]  K. Downing,et al.  Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. , 2000, Annual review of cell and developmental biology.

[39]  N. Wake,et al.  Expression of beta-tubulin isotypes in human primary ovarian carcinoma. , 2007, Gynecologic oncology.

[40]  O. Bernard,et al.  LIM Kinase 2 Is Widely Expressed in All Tissues , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  P. Tsvetkov,et al.  Stathmin/Op18 is a novel mediator of vinblastine activity , 2008, FEBS letters.

[42]  A. Paradiso,et al.  Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  V. Fedele,et al.  Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins , 2007 .

[44]  M. Lind,et al.  Do β-tubulin mutations have a role in resistance to chemotherapy? , 2004 .

[45]  F. Cabral,et al.  A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. , 2004, Molecular biology of the cell.

[46]  Maria Kavallaris,et al.  Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. , 2008, Cancer research.

[47]  J. Hunt.  Discovery of Ixabepilone , 2009, Molecular Cancer Therapeutics.

[48]  E. Martinelli,et al.  Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.

[49]  G. Scambia,et al.  Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.

[50]  A. Tramontano,et al.  The βI/βIII‐tubulin isoforms and their complexes with antimitotic agents , 2006 .

[51]  R. Luduena.  Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[52]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[53]  F. Cabral.  Factors determining cellular mechanisms of resistance to antimitotic drugs. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[54]  T. Nohara,et al.  Tau Expression and Efficacy of Paclitaxel Treatment in Metastatic Breast Cancer. , 2009 .

[55]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[56]  M. Monden,et al.  Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[58]  A. Levine,et al.  DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. , 1999, Cancer research.

[59]  S. Horwitz,et al.  Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. , 2003, Cancer research.

[60]  Conly L. Rieder,et al.  Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied , 2008, The Journal of cell biology.

[61]  M. Socinski,et al.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Di Michele,et al.  Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin , 2008, Molecular Cancer Therapeutics.

[63]  B. Liu,et al.  Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines. , 2001, World journal of gastroenterology.

[64]  R. Pepperkok,et al.  Microtubules are stabilized in confluent epithelial cells but not in fibroblasts , 1990, The Journal of cell biology.

[65]  Dawen Cai,et al.  Tubulin modifications and their cellular functions. , 2008, Current opinion in cell biology.

[66]  Jacek Gaertig,et al.  The Tubulin Code , 2007, Cell cycle.

[67]  D. Menick,et al.  Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. , 1999, Journal of cell science.

[68]  A. Portyanko,et al.  βIII-tubulin at the invasive margin of colorectal cancer: possible link to invasion , 2009, Virchows Archiv.

[69]  P. Giannakakou,et al.  The importance of p53 location: nuclear or cytoplasmic zip code? , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[70]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[71]  G. Atweh,et al.  The role of stathmin in the regulation of the cell cycle , 2004, Journal of cellular biochemistry.

[72]  P. Shen,et al.  Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1 , 2002 .

[73]  S. Nordeen,et al.  MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents , 2009, Molecular Cancer Therapeutics.

[74]  M. Kavallaris,et al.  The role of beta-tubulin isotypes in resistance to antimitotic drugs. , 2001, Biochimica et biophysica acta.

[75]  F. Lee,et al.  Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies , 2009, Molecular Cancer Therapeutics.

[76]  Y. Ohashi,et al.  Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. , 2009, Anticancer research.

[77]  J. Mackey,et al.  Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel , 2005, Molecular Cancer Therapeutics.

[78]  M. Kavallaris.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews. Cancer.

[79]  E. Pasquier,et al.  Microtubules: A dynamic target in cancer therapy , 2008, IUBMB life.

[80]  P. Sabbatini,et al.  Epothilones: better or more of the same? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  F. Lovat,et al.  Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. , 2008, Molecular biology of the cell.

[82]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. Hruban,et al.  Class III β‐tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia , 2007, Histopathology.

[84]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[85]  G. Scambia,et al.  Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? , 2007, Current cancer drug targets.

[86]  Roman Rouzier,et al.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Alan Hall,et al.  The cytoskeleton and cancer , 2009, Cancer and Metastasis Reviews.

[88]  M. Kirschner,et al.  Microtubule dynamics , 1986, Nature.

[89]  O. Bernard,et al.  LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs , 2010, Oncogene.

[90]  W. Hait,et al.  A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  R. Li,et al.  Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim , 2005, Cell Death and Differentiation.

[92]  D. Larsimont,et al.  Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. , 2002, Clinical breast cancer.

[93]  C. Dumontet,et al.  Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β‐tubulin , 2009, Journal of cellular physiology.

[94]  Jack A. Tuszynski,et al.  Identification and Characterization of an Intermediate Taxol Binding Site Within Microtubule Nanopores and a Mechanism for Tubulin Isotype Binding Selectivity , 2009, J. Chem. Inf. Model..

[95]  M. Kavallaris,et al.  Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol , 1999, British Journal of Cancer.

[96]  M. Steinmetz,et al.  Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.

[97]  G. Scambia,et al.  Molecular mechanisms of patupilone resistance. , 2008, Cancer research.

[98]  K. Bhalla.  Microtubule-targeted anticancer agents and apoptosis , 2003, Oncogene.

[99]  T. Masuda,et al.  Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. , 2009, The Journal of investigative dermatology.

[100]  G. Borisy,et al.  Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis , 1996, The Journal of cell biology.

[101]  E D Salmon,et al.  Tubulin dynamics in cultured mammalian cells , 1984, The Journal of cell biology.

[102]  C. Rieder,et al.  The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. , 2009, Cell motility and the cytoskeleton.

[103]  Anthony A. Hyman,et al.  Dynamics and mechanics of the microtubule plus end , 2022 .

[104]  C. Caldas,et al.  The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel , 2007, Cancer cell.

[105]  J. Baselga,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  M. Carré,et al.  Microtubules in apoptosis induction: are they necessary? , 2007, Current cancer drug targets.

[107]  R. Angeletti,et al.  Tubulin proteomics: towards breaking the code. , 2009, Analytical biochemistry.

[108]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[109]  Shushan Rana,et al.  Stathmin 1: a novel therapeutic target for anticancer activity , 2008, Expert review of anticancer therapy.

[110]  J. Matthews,et al.  The role of polymorphisms at beta tubulin isotype 1 codons 167 and 200 in benzimidazole resistance in cyathostomins. , 2008, International journal for parasitology.

[111]  T. Mitchison,et al.  Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. , 2008, Cancer research.